Current antineoplastic treatments are not sufficient to cure cancer, in part due to lack efficacy and/or selectivity. Further, they often display significant side effects calling for new therapeutic approaches.
The invention consists in the design, realization and administration of peptides that target hexokinase 2 (HK2) specifically in tumors and display antineoplastic activity.
HK2 is glycolytic enzyme that contributes to metabolism, growth and death inhibition of tumor cells. Its expression is associated with poor prognosis and chemotherapeutic/radiation resistance in diverse solid and hematopoietic tumors.

TRL (Technology Readiness Level)

Lead Optimization/Preclinical

Inventors

Andrea Rasola

Francesco Ciscato

Paolo Bernardi

Download the brochure

Share this

Facebook
Twitter
Linkedin
Email

  • TREM2MICROENGINES – Novel Regulated Promoter for Gene Therapy

    Neuroinflammation, characterized by microglial cell-activation, plays a major role in the pathogenesis and progression of multiple neurodegenerative diseases, such as Lysosomal Storage Disorders and Alzheimer’s, severe human conditions currently lacking an effective treatment. Ex vivo gene therapy based on genetically...

  • Small molecule inhibitors of OPA1 GTPase activity with anti-cancer properties

    Cancer is a complex disease resulting from the interplay between the tumor cell and its microenvironment, featuring impaired apoptosis and activation of quiescent blood vessels to induce neovascularization to support metastasis. Two of the yet unmet needs in anticancer therapy...

  • Bicyclic peptides for targeted therapy against cancer

    Since inhibitors based on small molecules and macromolecules are not selective and potent enough, new compounds, including bicyclic peptides, have been developed in recent years. Bicyclic peptides are new generation therapeutic molecules which exhibit properties typical of monoclonal antibodies (high...

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation